144 related articles for article (PubMed ID: 21679088)
1. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
Dienstmann R; Felip E
Expert Opin Biol Ther; 2011 Sep; 11(9):1223-31. PubMed ID: 21679088
[TBL] [Abstract][Full Text] [Related]
2. Necitumumab for non-small cell lung cancer.
Greillier L; Tomasini P; Barlesi F
Expert Opin Biol Ther; 2015; 15(8):1231-9. PubMed ID: 26051700
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
Pirker R
Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
[TBL] [Abstract][Full Text] [Related]
4. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
Di Maio M
Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
[TBL] [Abstract][Full Text] [Related]
5. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.
Dienstmann R; Tabernero J
Curr Opin Investig Drugs; 2010 Dec; 11(12):1434-41. PubMed ID: 21154125
[TBL] [Abstract][Full Text] [Related]
6. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
7. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against EGFR in non-small cell lung cancer.
Pirker R; Filipits M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
10. Necitumumab for the treatment of squamous cell non-small cell lung cancer.
Brinkmeyer JK; Moore DC
J Oncol Pharm Pract; 2018 Jan; 24(1):37-41. PubMed ID: 27913776
[TBL] [Abstract][Full Text] [Related]
11. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Kim DW; Choy H
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
[TBL] [Abstract][Full Text] [Related]
12. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C; Ardizzoni A; Douillard JY; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F
Lung Cancer; 2010 Jun; 68(3):319-31. PubMed ID: 20036027
[TBL] [Abstract][Full Text] [Related]
13. Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
di Noia V; D'Argento E; Pilotto S; Grizzi G; Caccese M; Iacovelli R; Tortora G; Bria E
Expert Opin Biol Ther; 2018 Sep; 18(9):937-945. PubMed ID: 30075697
[TBL] [Abstract][Full Text] [Related]
14. Necitumumab for the treatment of advanced non-small-cell lung cancer.
Díaz-Serrano A; Sánchez-Torre A; Paz-Ares L
Future Oncol; 2019 Mar; 15(7):705-716. PubMed ID: 30501503
[TBL] [Abstract][Full Text] [Related]
15. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Expert Rev Respir Med; 2015 Jun; 9(3):245-54. PubMed ID: 25797462
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for cetuximab in non small cell lung cancer?
Morgensztern D; Govindan R
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies.
Siena S; Artale S; Vanzulli A; Marrapese G; Bevilacqua L; Secondino S; Sironi O; Schiavo R; Moroni M; Pedrazzoli P
Suppl Tumori; 2002; 1(4):S46-8. PubMed ID: 12415818
[No Abstract] [Full Text] [Related]
18. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
19. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
[TBL] [Abstract][Full Text] [Related]
20. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
